Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study

This research was supported by funding for the Leo Epidemiology of Outcomes Study (1U01CA195568-01) and T32 CA244125 (M.A.S.) R.S. has research funding from Seagen/Pfizer, BMS, GSK, Rafael Pharmaceuticals, and NCI. C.F. has received consulting fees from Abbvie, Bayer, BeiGene, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, N-Power Medicine, Pharmacyclics/Janssen, SeaGen, Spectrum, and has research funding from 4D, Abbvie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, BostonGene, Celgene, Cellectis EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation, Cancer Prevention and Research Institute of Texas (RR190079): CPRIT Scholar in Cancer Research. M.M. has research funding from BMS, Roche/Genentech, and GenMab, and is involved in the advisory board/consulting for BMS, GenMab, AstraZeneca, Adaptive Biotechnology.